A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury

Richard Schwameis, Sandra Eder, Helmut Pietschmann, Bernhard Fischer, Hermann Mascher, Susan Tzotzos, Hendrik Fischer, Rudolf Lucas, Markus Zeitlinger, Robert Hermann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

AP301 is an activator of ENaC-mediated Na+ uptake for the treatment of pulmonary permeability edema in acute respiratory distress syndrome (ARDS). The purpose of this "first-in-man" study was to examine local and systemic safety and systemic exposure of ascending single doses of AP301, when inhaled by healthy male subjects. In a double-blind, placebo-controlled study, 48 healthy male subjects were randomized to 6 ascending dose groups (single doses up to 120 mg) of 8 subjects each (3:1 randomization of AP301: placebo). Serial assessments included spirometry, exhaled nitric oxide (eNO), vital signs, ECG, safety laboratory, adverse events (AE), and blood samples for the quantification of AP301 in plasma. Descriptive statistics was applied. All 48 subjects received treatment, and completed the study as per protocol. No serious, local (e.g., hoarseness, cough, bronchospasm), or dose-limiting AEs were noted. None of the assessments indicated notable dose or time-related alterations of safety outcomes. Observed AP301 systemic exposure levels were very low, with mean Cmax values of <2.5 ng/mL in the highest dose groups. Inhaled AP301 single doses up to 120 mg were safe and well tolerated by healthy male subjects. Distribution of inhaled AP301 was largely confined to the lung, as indicated by very low AP301 systemic exposure levels.

Original languageEnglish (US)
Pages (from-to)341-350
Number of pages10
JournalJournal of Clinical Pharmacology
Volume54
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Acute Lung Injury
Healthy Volunteers
Safety
Placebos
Hoarseness
Bronchial Spasm
Vital Signs
Spirometry
Adult Respiratory Distress Syndrome
Pulmonary Edema
Random Allocation
Cough
Permeability
Nitric Oxide
Electrocardiography
Therapeutics
Lung

Keywords

  • AP301
  • ARDS
  • ENaC activator
  • first-in-man study

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury. / Schwameis, Richard; Eder, Sandra; Pietschmann, Helmut; Fischer, Bernhard; Mascher, Hermann; Tzotzos, Susan; Fischer, Hendrik; Lucas, Rudolf; Zeitlinger, Markus; Hermann, Robert.

In: Journal of Clinical Pharmacology, Vol. 54, No. 3, 01.01.2014, p. 341-350.

Research output: Contribution to journalArticle

Schwameis, R, Eder, S, Pietschmann, H, Fischer, B, Mascher, H, Tzotzos, S, Fischer, H, Lucas, R, Zeitlinger, M & Hermann, R 2014, 'A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury', Journal of Clinical Pharmacology, vol. 54, no. 3, pp. 341-350. https://doi.org/10.1002/jcph.203
Schwameis, Richard ; Eder, Sandra ; Pietschmann, Helmut ; Fischer, Bernhard ; Mascher, Hermann ; Tzotzos, Susan ; Fischer, Hendrik ; Lucas, Rudolf ; Zeitlinger, Markus ; Hermann, Robert. / A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury. In: Journal of Clinical Pharmacology. 2014 ; Vol. 54, No. 3. pp. 341-350.
@article{530c0d1443e34977bc07d92b633bbca4,
title = "A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury",
abstract = "AP301 is an activator of ENaC-mediated Na+ uptake for the treatment of pulmonary permeability edema in acute respiratory distress syndrome (ARDS). The purpose of this {"}first-in-man{"} study was to examine local and systemic safety and systemic exposure of ascending single doses of AP301, when inhaled by healthy male subjects. In a double-blind, placebo-controlled study, 48 healthy male subjects were randomized to 6 ascending dose groups (single doses up to 120 mg) of 8 subjects each (3:1 randomization of AP301: placebo). Serial assessments included spirometry, exhaled nitric oxide (eNO), vital signs, ECG, safety laboratory, adverse events (AE), and blood samples for the quantification of AP301 in plasma. Descriptive statistics was applied. All 48 subjects received treatment, and completed the study as per protocol. No serious, local (e.g., hoarseness, cough, bronchospasm), or dose-limiting AEs were noted. None of the assessments indicated notable dose or time-related alterations of safety outcomes. Observed AP301 systemic exposure levels were very low, with mean Cmax values of <2.5 ng/mL in the highest dose groups. Inhaled AP301 single doses up to 120 mg were safe and well tolerated by healthy male subjects. Distribution of inhaled AP301 was largely confined to the lung, as indicated by very low AP301 systemic exposure levels.",
keywords = "AP301, ARDS, ENaC activator, first-in-man study",
author = "Richard Schwameis and Sandra Eder and Helmut Pietschmann and Bernhard Fischer and Hermann Mascher and Susan Tzotzos and Hendrik Fischer and Rudolf Lucas and Markus Zeitlinger and Robert Hermann",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/jcph.203",
language = "English (US)",
volume = "54",
pages = "341--350",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - A FIM study to assess safety and exposure of inhaled single doses of AP301 - A specific ENaC channel activator for the treatment of acute lung injury

AU - Schwameis, Richard

AU - Eder, Sandra

AU - Pietschmann, Helmut

AU - Fischer, Bernhard

AU - Mascher, Hermann

AU - Tzotzos, Susan

AU - Fischer, Hendrik

AU - Lucas, Rudolf

AU - Zeitlinger, Markus

AU - Hermann, Robert

PY - 2014/1/1

Y1 - 2014/1/1

N2 - AP301 is an activator of ENaC-mediated Na+ uptake for the treatment of pulmonary permeability edema in acute respiratory distress syndrome (ARDS). The purpose of this "first-in-man" study was to examine local and systemic safety and systemic exposure of ascending single doses of AP301, when inhaled by healthy male subjects. In a double-blind, placebo-controlled study, 48 healthy male subjects were randomized to 6 ascending dose groups (single doses up to 120 mg) of 8 subjects each (3:1 randomization of AP301: placebo). Serial assessments included spirometry, exhaled nitric oxide (eNO), vital signs, ECG, safety laboratory, adverse events (AE), and blood samples for the quantification of AP301 in plasma. Descriptive statistics was applied. All 48 subjects received treatment, and completed the study as per protocol. No serious, local (e.g., hoarseness, cough, bronchospasm), or dose-limiting AEs were noted. None of the assessments indicated notable dose or time-related alterations of safety outcomes. Observed AP301 systemic exposure levels were very low, with mean Cmax values of <2.5 ng/mL in the highest dose groups. Inhaled AP301 single doses up to 120 mg were safe and well tolerated by healthy male subjects. Distribution of inhaled AP301 was largely confined to the lung, as indicated by very low AP301 systemic exposure levels.

AB - AP301 is an activator of ENaC-mediated Na+ uptake for the treatment of pulmonary permeability edema in acute respiratory distress syndrome (ARDS). The purpose of this "first-in-man" study was to examine local and systemic safety and systemic exposure of ascending single doses of AP301, when inhaled by healthy male subjects. In a double-blind, placebo-controlled study, 48 healthy male subjects were randomized to 6 ascending dose groups (single doses up to 120 mg) of 8 subjects each (3:1 randomization of AP301: placebo). Serial assessments included spirometry, exhaled nitric oxide (eNO), vital signs, ECG, safety laboratory, adverse events (AE), and blood samples for the quantification of AP301 in plasma. Descriptive statistics was applied. All 48 subjects received treatment, and completed the study as per protocol. No serious, local (e.g., hoarseness, cough, bronchospasm), or dose-limiting AEs were noted. None of the assessments indicated notable dose or time-related alterations of safety outcomes. Observed AP301 systemic exposure levels were very low, with mean Cmax values of <2.5 ng/mL in the highest dose groups. Inhaled AP301 single doses up to 120 mg were safe and well tolerated by healthy male subjects. Distribution of inhaled AP301 was largely confined to the lung, as indicated by very low AP301 systemic exposure levels.

KW - AP301

KW - ARDS

KW - ENaC activator

KW - first-in-man study

UR - http://www.scopus.com/inward/record.url?scp=84898639896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898639896&partnerID=8YFLogxK

U2 - 10.1002/jcph.203

DO - 10.1002/jcph.203

M3 - Article

VL - 54

SP - 341

EP - 350

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 3

ER -